Independent Signal
A focused analysis can be run before seeing the existing shortlist, then compared on overlap, incremental signal, contradictions, and decision impact.
COMPANY
Independent oncology development intelligence for decisions before and alongside execution.
OncoLattice helps oncology sponsors—especially Chinese biotechs going global—validate material development assumptions with transparent evidence and clinically reviewed reasoning.
Focused independent validation, complementary to CRO execution.
CROs bring broad data, technology, operational experience, and execution capability. OncoLattice adds a focused sponsor-side intelligence layer that can be tested against the current plan.
Visible Reasoning
Sources, assumptions, estimates, inference, conflicting evidence, uncertainty, and reviewer status stay visible.
Oncology Context
Evidence is interpreted through disease, biomarker, treatment line, testing pathway, competition, protocol fit, and patient reality.
Decision Discipline
The engagement begins with one fixed question, clear success criteria, and boundaries around what the evidence can support.
Commercial direction and clinical intelligence are led together.
Zhipei (Kevin) Luo
Leads company strategy, product direction, sponsor and partner conversations, and cross-border commercial development.
Dr. Allen Lunhsiang Yuan
Leads technology and data-platform direction, clinical intelligence methodology, and clinical interpretation of technical outputs.
OncoLattice does not replace CRO execution, sponsor governance, medical judgment, regulatory counsel, or legal review.
START WITH ONE DECISION
A focused pilot begins with a fixed question.
The first engagement is designed to produce an independent signal that can be compared with the sponsor's or CRO's current view.
Outputs are for strategic planning and do not guarantee patient availability, enrollment, site performance, regulatory outcomes, or clinical success.